SenzaGen Q1: Solid sales and EBITDA break even - Redeye

Redeye provides an update following SenzaGen’s Q1 report. Sales during the quarter aligned with our expectations; however, we highlight the quarterly EBITDA and argue that SenzaGen is one step closer to profitability. We only make some minor estimate changes and our fair value range remains intact.

Länk till analysen i sin helhet: https://www.redeye.se/research/1007914/senzagen-q1-solid-sales-and-ebitda-break-even?utm_source=finwire&utm_medium=RSS